Literature DB >> 10585810

An outbreak of acute respiratory disease caused by Mycoplasma pneumoniae and adenovirus at a federal service training academy: new implications from an old scenario.

D R Feikin1, J F Moroney, D F Talkington, W L Thacker, J E Code, L A Schwartz, D D Erdman, J C Butler, M S Cetron.   

Abstract

Outbreaks of Mycoplasma pneumoniae and adenovirus have been reported in military institutions for several decades. During a recent outbreak in a federal service training academy, we performed an epidemiological and laboratory investigation to better characterize and control the outbreak. Of 586 students responding to a questionnaire, 317 (54%) reported having a respiratory illness during the outbreak period. Among 42 students who underwent complete laboratory testing, 24 (57%) had evidence of M. pneumoniae infection, 8 (19%) had evidence of adenovirus infection, and 4 (10%) had evidence of both. Polymerase chain reaction testing of oropharyngeal swabs revealed more acute M. pneumoniae infections (57% positive) than did serology or culture. Multivariate analysis revealed that visiting the campus health clinic >3 times for a nonrespiratory condition, such as injury, was a significant risk factor for illness among freshmen early in the course of the outbreak, whereas having an ill roommate was a risk factor throughout the duration of the outbreak.

Entities:  

Mesh:

Year:  1999        PMID: 10585810     DOI: 10.1086/313500

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  13 in total

1.  Mycoplasma pneumoniae Outbreaks on Navy Vessels.

Authors:  Ran Nir-Paz
Journal:  J Clin Microbiol       Date:  2010-05       Impact factor: 5.948

2.  Epidemiology and Molecular Characteristics of Mycoplasma pneumoniae During an Outbreak of M. pneumoniae-associated Stevens-Johnson Syndrome.

Authors:  Louise K Francois Watkins; Daniel Olson; Maureen H Diaz; Xia Lin; Alicia Demirjian; Alvaro J Benitez; Jonas M Winchell; Christine C Robinson; Kirk A Bol; Mary P Glodé; Samuel R Dominguez; Lisa A Miller; Preeta K Kutty
Journal:  Pediatr Infect Dis J       Date:  2017-06       Impact factor: 2.129

3.  Mycoplasma pneumoniae respiratory tract infections among Greek children.

Authors:  M Almasri; E Diza; A Papa; M Eboriadou; E Souliou
Journal:  Hippokratia       Date:  2011-04       Impact factor: 0.471

Review 4.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

5.  Applying network theory to epidemics: control measures for Mycoplasma pneumoniae outbreaks.

Authors:  Lauren Ancel Meyers; M E J Newman; Michael Martin; Stephanie Schrag
Journal:  Emerg Infect Dis       Date:  2003-02       Impact factor: 6.883

6.  Control of a Mycoplasma pneumoniae Outbreak in an Institutional Setting Using Azithromycin Prophylaxis.

Authors:  Michael Gdalevich; Eric J Haas; Larisa Dukhan; Manuel Katz; Victoria Zelenski; Jacob Moran-Gilad
Journal:  Front Public Health       Date:  2018-01-22

7.  The Enduring Challenge of Determining Pneumonia Etiology in Children: Considerations for Future Research Priorities.

Authors:  Daniel R Feikin; Laura L Hammitt; David R Murdoch; Katherine L O'Brien; J Anthony G Scott
Journal:  Clin Infect Dis       Date:  2017-06-15       Impact factor: 9.079

8.  Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection.

Authors:  Anna C Nilsson; Per Björkman; Kenneth Persson
Journal:  BMC Microbiol       Date:  2008-06-11       Impact factor: 3.605

9.  Climate variability and nonstationary dynamics of Mycoplasma pneumoniae pneumonia in Japan.

Authors:  Daisuke Onozuka; Luis Fernando Chaves
Journal:  PLoS One       Date:  2014-04-16       Impact factor: 3.240

Review 10.  A Compendium for Mycoplasma pneumoniae.

Authors:  Gretchen L Parrott; Takeshi Kinjo; Jiro Fujita
Journal:  Front Microbiol       Date:  2016-04-12       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.